Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 10, 26

The Effects of Thiopurine Therapy on Health-Related Quality of Life in Inflammatory Bowel Disease Patients


The Effects of Thiopurine Therapy on Health-Related Quality of Life in Inflammatory Bowel Disease Patients

Guillermo Bastida et al. BMC Gastroenterol.


Background: The effect of thiopurine immunomodulators on health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) has been controversial. The aims were to evaluate the HRQoL in patients with IBD treated with thiopurines and assess the short- and long-term impacts of the treatment on HRQoL.

Methods: Ninety-two consecutive patients who started treatment with thiopurines were prospectively included. Evaluation of HRQoL was performed at months 0, 6, and 12 using two questionnaires, the Short-Form Health Survey (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ).

Results: Baseline score of IBDQ was 4,6, range (2,31-6,84), with an impairment of the five dimensions of HRQoL compared with inactive patients. Results obtained in 8 dimensions of SF-36 showed worse HRQoL than Spanish general population. At 6 months patients had a significant improvement in overall IBDQ score -5,8 (1,58 -6,97)- and also in all IBDQ dimensions. All the 8 dimensions of SF-36 obtained a significant improvement. At twelve months score of IBDQ was 6,1, range (2,7-6,98), with improvement in all dimensions compared with baseline and 6 months. SF-36 showed a similar significant improvement in all subscales.

Conclusions: Thiopurine immunomodulators alone or with other treatments have a positive and long lasting impact on HRQoL of IBD patients.


Figure 1
Figure 1
SF-36 mean scale scores of Crohn's disease and ulcerative colitis patients in comparison to Spanish general population reference values. PF: Physical Functioning, RP: Role physical, BP: Bodily Pain, GH: General health, VT: Vitality, SF: Social functioning, RE: Role emotional, MH: Mental health.

Similar articles

See all similar articles

Cited by 8 PubMed Central articles

See all "Cited by" articles


    1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627–40. doi: 10.1016/S0140-6736(07)60750-8. - DOI - PubMed
    1. Love JR, Irvine EJ, Fedorak RN. Quality of life in IBD. J Clinical Gastroenterology. 1992;14:15–19. - PubMed
    1. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, McDonald JW. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287–96. - PubMed
    1. Casellas F, Arenas JI, Baudet JS, Fábregas S, García N, Gelabert J, Medina C, Ochotorena I, Papo M, Rodrigo L, Malagelada JR. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11:488–96. doi: 10.1097/01.MIB.0000159661.55028.56. - DOI - PubMed
    1. Rubin GP, Hungin AP, Chinn DJ, Dwarakanath D. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther. 2004;19:529–35. doi: 10.1111/j.1365-2036.2004.1873.x. - DOI - PubMed

Publication types

MeSH terms